Latest news
{{'2024-11-01T12:13:24Z' | dateFormatFilter}}
Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
Read more
{{'2024-10-21T09:26:27Z' | dateFormatFilter}}
Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
Read more
{{'2024-10-18T09:32:29Z' | dateFormatFilter}}
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
Read more
Our corporate governance practices take into consideration applicable regulations, corporate governance codes and the Novo Nordisk Way.
Find our more about how we manage our business:
See all our financial results from today and back to 2016, including Annual reports, Quarterly company announcements with financial results, investor presentations, financial workbooks as well as the webcast and presentation from the different investor events like Capital Markets Day.
We are committed to providing therapies and innovative injection devices for patients with diabetes, obesity, and other serious chronic conditions, including haemophilia and growth hormone disorder.
Learn more below about our medicines and broad range of devices.
We have nearly a century of expertise working with proteins and peptides. In recent years, we have increased our research technology platforms to include stem cells, RNA interference and genome editing. To realise the full potential of these research technologies, we are pioneering scientific innovation together with our external partners.
Our R&D pipeline reflects our long-standing commitment to driving
change to defeat diabetes and other serious chronic conditions.
Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, haemophilia, growth disorders and non-alcoholic steatohepatitis (NASH).
Browse our entire R&D pipeline by study phase, or select a specific therapy areas
Access and affordability
We will not allow the success
of our company to be defined by the steady increase in the number of
people living with serious chronic diseases, like type 2 diabetes and
obesity. Our success will be defined by the solutions we bring and the
health and well-being of the people and communities benefiting from them.
Learn more about our strategy to defeat diabetes.
Environmental responsibility
We are the
first pharmaceutical company to use 100% renewable power in all our
global production facilities. We are proud but also motivated to go
even further. With our Circular for Zero
strategy, we are starting a journey to achieve zero
environmental impact in all our business activities.
We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases.
We employ more than 64,000 people in 80 offices around the world, and market our products in 170 countries.
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
